Advertisement

A Randomized Pilot Study of SRL172 (Mycobacterium vaccae) in Patients with Small Cell Lung Cancer (SCLC) Treated with Chemotherapy

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Background:
      SRL172 is a suspension of heat killed Mycobacterium vaccae, that has been found to be a potent immunological adjuvant when used with autologous cells in animal models. This is a phase II study to test the clinical activity, feasibility and safety of combining SRL172 with chemotherapy to treat patients with small cell lung cancer (SCLC).
      Methods:
      Patients were randomized to receive chemotherapy with (n=14) or without (n=14) SRL172. The chemotherapy was either platinum-based (MVP, n=10) or anthracycline-based (ACE, n=18). SRL172 was given intradermally on day 0, weeks 4, 8 and then 3–6 monthly.
      Results:
      The treatment arms were well balanced for disease extent (43% with limited stage in each arm). The toxicity of chemotherapy and overall response at 12–15 weeks (57%) was the same for both treatment regimens. Median survival was 8.6 months and 12.9 for patients treated with chemotherapy alone and with the combination respectively (P=0.10). The survival trend was similar for both disease extent and chemotherapy regimen employed in favour of combination chemotherapy with SRL172.
      Conclusions:
      There is a trend to improved median survival in SCLC with the combination of chemotherapy and SRL172 with no increased toxicity and irrespective of drug regimen. A phase III study examining chemotherapy in combination with SRL172 in SCLC is now underway..

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Clinical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Zochbauer-Muller S
        • Pirker R
        • Huber H
        Treatment of small cell lung cancer patients.
        Ann Oncol. 1999; 10: 83-91
        • Kelly K
        New chemotherapy agents for small cell lung cancer.
        Cancer. 2000; 117: 156S-162S
        • Ardizzoni A
        • Grossi F
        Update on the treatment of small cell lung cancer (SCLC).
        Ann Oncol. 2000; 11: 101-108
        • Mendes R
        • O'Brien M
        • Bromelow K
        A highly active regimen for malignant mesothelioma with new biological data.
        Br J Cancer. 2000; 83: 7.8
        • O'Brien M
        • Saini A
        • Smith I
        A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma.
        Br J Cancer. 2000; 83: 853-857
        • Grant SC
        • Kris MG
        • Miller V
        • Yao TJ
        • Houghton AN
        • Chapman PB
        Long survival in 15 patients with small cell lung cancer (SCLC) immunized with BEC2 plus BCG after initial therapy: An update.
        Proc ASCO. 1997; 16: 1630
        • Maraveyas A
        • Baban B
        • Kennard D
        Possible improved survival of patients with stage IVAJCC melanoma receiving SRL172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes.
        Ann Oncol. 1999; 10: 817-824
        • Hrouda D
        • Baban B
        • Dunsmuir W
        • Kirby R
        • Dalgleish A
        Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172).
        Br J Urol. 1998; 82: 568-573
        • Hickish T
        • Smith I
        • Nicolson M
        A pilot study of MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in small-cell lung cancer.
        Br J Cancer. 1998; 77: 1966-1970
        • Noda K
        • Nishiwaki Y
        • Kawahara M
        Randomized Phase III study or irinotecan (CPT-11) and cisplatin versus etoposide and cisplatin in extensive disease small cell lung cancer: Japan Clinical Oncology Group study (JCOG9511).
        Proc ASCO. 2000; 19: 1887